Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors
- Kazuhiko Nakagawa
- , Hironobu Minami
- , Masayuki Kanezaki
- , Akihira Mukaiyama
- , Yoshiyuki Minamide
- , Hisao Uejima
- , Takayasu Kurata
- , Toshiji Nogami
- , Kenji Kawada
- , Hirofumi Mukai
- , Yasutsuna Sasaki
- , Masahiro Fukuoka
研究成果: ジャーナルへの寄稿 › 学術論文 › 査読
21
リンクは新しいタブで開きます
被引用数
(Scopus)